Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Immune Design Corp. (NASDAQ: IMDZ).

Full DD Report for IMDZ

You must become a subscriber to view this report.


Recent News from (NASDAQ: IMDZ)

Investor Expectations to Drive Momentum within CSW Industrials, On Deck Capital, Hurco Companies, PetMed Express, Sandstorm Gold, and Immune Design - Discovering Underlying Factors of Influence
NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CSW Industrials, Inc. (NASDAQ:CSWI), On Deck Capital, Inc. (NYSE:ONDK), ...
Source: GlobeNewswire
Date: September, 05 2018 07:35
Immune Design to Present at Upcoming September Investor Conferences
SEATTLE and SOUTH SAN FRANCISCO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that senior management will present at the following upcoming investor conferences: 13 th Annual Wells Fargo...
Source: GlobeNewswire
Date: August, 30 2018 08:00
Consolidated Research: 2018 Summary Expectations for FTD Companies, PRA Group, Equity Bancshares, ConforMIS, Immune Design, and Imprimis Pharmaceuticals - Fundamental Analysis, Key Performance Indications
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FTD Companies, Inc. (NASDAQ:FTD), PRA Group, Inc. (NASDAQ:PRAA), Equity B...
Source: GlobeNewswire
Date: August, 15 2018 07:50
Immune Design Corp.'s (IMDZ) CEO Carlos Paya on Q2 2018 Results - Earnings Call Transcript
Immune Design Corp. (IMDZ) Q2 2018 Results Earnings Conference Call August 1, 2018, 04:30 PM ET Executives Sylvia Wheeler - Investor Relations Group Carlos Paya - President and CEO Sergey Yurasov - SVP, Clinical Development and CMO Stephen Brady - EVP, Strategy and Finance A...
Source: SeekingAlpha
Date: August, 01 2018 21:48
Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update
G100 advancing to late-stage development following FDA feedback Conference call at 1:30 pm Pacific today SEATTLE, WA and SOUTH SAN FRANCISCO, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, t...
Source: GlobeNewswire
Date: August, 01 2018 16:01
Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report second quarter 2018 financial results after the close of U.S. financial mark...
Source: GlobeNewswire
Date: July, 25 2018 08:00
Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma
- G100 directly targets and modifies TLR4 expressing malignant B cells making them more visible to the anti-tumor immune response- SEATTLE and SOUTH SAN FRANCISCO, Calif., June 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on novel therapi...
Source: GlobeNewswire
Date: June, 25 2018 08:00
Week 25 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 25: Market conditions continue with high volatility. The positive momentum gauge continues with another full week in yellow (medium) moving from a value of 60 at the end of the prior week down to a value of 44 this week. The all time low for the posit...
Source: SeekingAlpha
Date: June, 18 2018 01:15
A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals
Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for...
Source: SeekingAlpha
Date: June, 16 2018 09:00
Is Immune Design Worth A Second Look?
Shares of Immune Design ( IMDZ ) have fallen by more than 80% in the past three years. Year to date the stock is in the green by around 9%. Chart Figure 1: IMDZ daily advanced chart (Source: Finviz) Figure 2: IMDZ 15-minute chart (Source: Finviz) When looking at charts, cla...
Source: SeekingAlpha
Date: June, 12 2018 14:41

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-083.503.503.553.40102,969
2018-05-174.504.454.504.15375,623
2017-02-035.405.705.755.4030,752
2017-02-025.605.355.705.3059,648
2017-02-015.805.655.955.6039,925

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1443,872110,39839.7399Short
2018-12-1329,358102,41328.6663Cover
2018-12-1229,01278,80536.8149Short
2018-12-1199,106202,99648.8217Short
2018-12-10124,366416,96529.8265Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IMDZ.


About Immune Design Corp. (NASDAQ: IMDZ)

Logo for Immune Design Corp. (NASDAQ: IMDZ)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: IMDZ)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 03 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Written public communication relating to an issuer or third party tender offer not by the subject company
      Filing Type: SC TO-CFiling Source: edgar
      Filing Date: April, 26 2018
      Preliminary proxy statement providing notification matters to be brought to a vote
      Filing Type: PRE 14AFiling Source: edgar
      Filing Date: April, 10 2018
      Written public communication relating to an issuer or third party tender offer not by the subject company
      Filing Type: SC TO-CFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 14 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 14 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 14 2018
      Amendment to the SC 13G filing
      Filing Type: SC 13G/AFiling Source: edgar
      Filing Date: February, 14 2018

       

       


      Daily Technical Chart for (NASDAQ: IMDZ)

      Daily Technical Chart for (NASDAQ: IMDZ)


      Stay tuned for daily updates and more on (NASDAQ: IMDZ)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: IMDZ)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IMDZ is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IMDZ and does not buy, sell, or trade any shares of IMDZ. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/